Thursday, January 27, 2022

Pfizer Moves to Intervene in High-Profile Case Dealing With COVID-19 Vaccine Safety Data

Pfizer has asked a federal court to let it intervene in a high-profile case that has seen U.S. drug regulators try to slow-walk disclosure of data on Pfizer's COVID-19 vaccine.

About two weeks after the order, on Jan. 21, lawyers representing Pfizer asked U.S. District Judge Mark Pittman, a Trump nominee overseeing the case, to allow the company to intervene.

Pfizer was not aware of the case until executives read news reports about it last month and now wants to help FDA staffers review the documents in question to ensure proper redactions are made, according to the new filing.

In light of the FDA's objections to the sped-up timeframe, Pfizer "Seeks leave to intervene in this action for the limited purpose of ensuring that information exempt from disclosure under FOIA is adequately protected as FDA complies with this Court's order," the memorandum supporting the motion for leave to intervene stated.

"Even though the FDA has more than sufficient resources to expeditiously produce the requested documents, and the agency has repeatedly stated its commitment to protecting Pfizer's interests, Pfizer could still assist the FDA with expediting release of the requested documents. Pfizer provides no reason why it needs to intervene in this matter to render that purported assistance. Nor can Plaintiff discern why Pfizer needs to intervene in this matter to assist the FDA with expediting release of the requested documents-it can render this assistance without intervening," Public Health and Medical Professionals for Transparency said in a brief.

"Pfizer does not presently intend to move the Court to reconsider its January 6, 2022 order, but Pfizer is not in a position at this time to waive its ability to do so if circumstances change such that there is good cause at a later time to do so," Daniel Tobey, one of Pfizer's lawyers, said in a statement to the court.

Plaintiffs are concerned that Pfizer's involvement will lead to the FDA renewing effort to delay production of the vaccine data.
 

https://www.theepochtimes.com/pfizer-moves-to-intervene-in-high-profile-case-dealing-with-covid-19-vaccine-safety-data_4238676.html?utm_source=newsnoe&utm_campaign=breaking-2022-01-26-4&utm_medium=email&est=0zA%2Bgn8z37ZuDn4%2Fq4uw47Fu7H1XBIDKEBkj%2BekVO8 

No comments: